Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Joemareon Feb 03, 2023 10:46am
135 Views
Post# 35264756

RE:RE:Paying a 2M$ salary to an executive that has not delivered

RE:RE:Paying a 2M$ salary to an executive that has not deliveredReducing his salary and still gets a pass for failure to bring shareholder value is still not an option.

Is there really something in the workd? They've had 6 months to figure that out, no, three years to figure that out. I think it's a dead-end with these guys. 

They will announce more bad news during the febuary call: my take: no more NASH, no more TH1908. No job cuts. They're putting the company for sale. The buyer will do all the dirty work for them.

They will try to modify their contracts to get golden parchutes. I hope I'm wrong as much at stake here. 
But, it started to smell funny 9 months ago....
<< Previous
Bullboard Posts
Next >>